- Home
- EML vs ACOG Comparison
EML vs ACOG Comparison
Compare EML & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- ACOG
- Stock Information
- Founded
- EML 1858
- ACOG 2000
- Country
- EML United States
- ACOG Canada
- Employees
- EML N/A
- ACOG N/A
- Industry
- EML Industrial Machinery/Components
- ACOG
- Sector
- EML Consumer Discretionary
- ACOG
- Exchange
- EML Nasdaq
- ACOG Nasdaq
- Market Cap
- EML 149.9M
- ACOG 129.6M
- IPO Year
- EML N/A
- ACOG N/A
- Fundamental
- Price
- EML $21.31
- ACOG $6.80
- Analyst Decision
- EML
- ACOG Strong Buy
- Analyst Count
- EML 0
- ACOG 1
- Target Price
- EML N/A
- ACOG $20.00
- AVG Volume (30 Days)
- EML 9.2K
- ACOG 92.2K
- Earning Date
- EML 11-04-2025
- ACOG 11-14-2025
- Dividend Yield
- EML 2.06%
- ACOG N/A
- EPS Growth
- EML N/A
- ACOG N/A
- EPS
- EML N/A
- ACOG N/A
- Revenue
- EML $269,054,445.00
- ACOG $4,586,341.00
- Revenue This Year
- EML $1.56
- ACOG N/A
- Revenue Next Year
- EML $7.00
- ACOG $149.89
- P/E Ratio
- EML $11.92
- ACOG N/A
- Revenue Growth
- EML 1.30
- ACOG N/A
- 52 Week Low
- EML $19.06
- ACOG $3.75
- 52 Week High
- EML $35.03
- ACOG $11.54
- Technical
- Relative Strength Index (RSI)
- EML 38.43
- ACOG 38.48
- Support Level
- EML $21.53
- ACOG $6.80
- Resistance Level
- EML $22.75
- ACOG $7.83
- Average True Range (ATR)
- EML 0.73
- ACOG 0.51
- MACD
- EML -0.16
- ACOG 0.00
- Stochastic Oscillator
- EML 9.64
- ACOG 34.39
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.